Drugs / Tiprelestat
Tiprelestat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07601295 | Jul 2026 → Feb 2030 expected | pulmonary arterial hypertension | Stanford University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tiprelestat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07601295 ↗ |
| Known as | Human elafin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108349 ↗ |
| Known as | Recombinant elafin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108349 ↗ |
| Route | Subcutaneous | “5 mg of tiprelestat in 1 mL saline administered as a daily subcutaneous injection for 168 days.” NCT07601295 ↗ |